FDA 483 - Mylan Laboratories Limited - May 24, 2024

Mylan Laboratories Limited in Sinnar, India, was cited for significant quality system deficiencies during an FDA inspection. Observations include inadequate investigation documentation, lack of control over laboratory records, unscientific root cause analyses, and poor facility and equipment maintenance. These issues indicate a systemic breakdown in quality control and data integrity practices.